Local Therapy Improves Survival in Metastatic Prostate Cancer

Bristow, 2002, Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis, J Clin Oncol, 20, 1248, 10.1200/JCO.2002.20.5.1248 Heng, 2014, Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium, Eur Urol, 66, 704, 10.1016/j.eururo.2014.05.034 Choueiri, 2011, The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy, J Urol, 185, 60, 10.1016/j.juro.2010.09.012 Mickisch, 2001, Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial, Lancet, 358, 966, 10.1016/S0140-6736(01)06103-7 Roviello, 2011, Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments, Surg Oncol, 20, e38, 10.1016/j.suronc.2010.09.002 Glehen, 2004, Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia, Lancet Oncol, 5, 219, 10.1016/S1470-2045(04)01425-1 Heidenreich, 2014, EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer, Eur Urol, 65, 467, 10.1016/j.eururo.2013.11.002 Antwi, 2014, Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis, Cancer Epidemiol, 38, 435, 10.1016/j.canep.2014.04.002 Culp, 2014, Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study, Eur Urol, 65, 1058, 10.1016/j.eururo.2013.11.012 Fossati, 2015, Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study, Eur Urol, 67, 3, 10.1016/j.eururo.2014.08.056 Satkunasivam, 2015, Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis, J Urol, 194, 378, 10.1016/j.juro.2015.02.084 Löppenberg, 2017, The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis, Eur Urol, 72, 14, 10.1016/j.eururo.2016.04.031 Gratzke, 2014, Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry, Eur Urol, 66, 602, 10.1016/j.eururo.2014.04.009 Sooriakumaran, 2016, A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation, Eur Urol, 69, 788, 10.1016/j.eururo.2015.05.023 Heidenreich, 2015, Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case–control study, J Urol, 193, 832, 10.1016/j.juro.2014.09.089 Gandaglia G, Fossati N, Stabile A, et al. Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-institution series with long-term follow-up. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.08.040. D’Agostino, 1998, Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group, Stat Med, 17, 2265, 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B Anderson, 1983, Analysis of survival by tumor response, J Clin Oncol, 1, 710, 10.1200/JCO.1983.1.11.710 Lin, 1998, Assessing the sensitivity of regression results to unmeasured confounders in observational studies, Biometrics, 54, 948, 10.2307/2533848 Mitra, 2007, Sensitivity of the hazard ratio to nonignorable treatment assignment in an observational study, Stat Med, 26, 1398, 10.1002/sim.2606 James, 2012, Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial, Lancet Oncol, 13, 549, 10.1016/S1470-2045(12)70088-8 Attard, 2014, Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial, Eur Urol, 66, 799, 10.1016/j.eururo.2014.05.038